drugset / Trial / NCT07594093

Safety and Drug Concentrations of REGN20934 in Adults With Overweight or Obesity

NCT07594093 ↗

Phase 1 Recruiting 90 enrolled Regeneron Pharmaceuticals
RandomizedSequentialQuadruple-blindTreatment

Summary

This study will test a study drug called REGN20934 to see how safe and well tolerated this drug is, as well as how the drug is processed in the body for participants with overweight or obesity. The study is looking at: * What side effects REGN20934 might cause * How much REGN20934 is in the blood at different times * If the body makes antibodies to REGN20934

Timeline

Start
2026-06-29
Primary completion
2027-02-22
Completion
2027-02-22

Drugs

EvaluationDrugModalityDoseRoute
Subject REGN20934 Unknown — —

Indications